AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2213800 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethicone/antacid (Asilone Gel)
Number of subjects: 53
Study 2213800 — intervention group
Group type: COMPARATOR
Intervention: Alginate/antacid (Gaviscon liquid)
Number of subjects: 53
Study 468672 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled histamine
Number of subjects: 12
Study 468672 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (10 mg)
Number of subjects: 12
Study 468672 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 30137529 — intervention group
Group type: EXPERIMENTAL
Intervention: TXT (one session of telephone counseling plus 2 weeks of text messaging; N = 44)
Number of subjects: 66
Study 30137529 — intervention group
Group type: COMPARATOR
Intervention: Standard Care control group (N = 22)
Number of subjects: 66
Study 28803333 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg TLV
Number of subjects: 43
Study 28803333 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg TLV
Number of subjects: 43
Study 28803333 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg TLV
Number of subjects: 43
Study 28803333 — intervention group
Group type: COMPARATOR
Intervention: Healthy adults (control)
Number of subjects: 43
Study 26248955 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for 12 weeks
Number of subjects: 104
Study 26248955 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for 24 weeks
Number of subjects: 104
Study 26248955 — intervention group
Group type: COMPARATOR
Intervention: Overall study population
Number of subjects: 104
Study 26248955 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for 24 weeks in genotype 1a patients
Number of subjects: 104
Study 26248955 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for 24 weeks in genotype 1b patients
Number of subjects: 104
Study 26248955 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin
Number of subjects: 104
Study 24917527 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention and oral health education before and after treatment
Number of subjects: 84
Study 24917527 — intervention group
Group type: COMPARATOR
Intervention: Regular doctor's advice after treatment (Control)
Number of subjects: 84
Study 21178180 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalline l-Thr added to basal diet (60% of NRC recommendation in Exp. 1 and 20-60% in Exp. 2)
Number of subjects: 14
Study 19414053 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose alcohol (0.2 g/kg)
Number of subjects: 0
Study 19414053 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose alcohol (0.4 g/kg)
Number of subjects: 0
Study 19414053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19414053 — intervention group
Group type: EXPERIMENTAL
Intervention: Task performance
Number of subjects: 0
Study 17589826 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard single bundle ACL reconstruction with lateral extraarticular reconstruction
Number of subjects: 20
Study 17589826 — intervention group
Group type: COMPARATOR
Intervention: Double bundle ACL reconstruction
Number of subjects: 20
Study 16336114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (family physical activity and parent education about diet and activity)
Number of subjects: 0
Study 16336114 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 0
Study 12151972 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (25 mg/m2 intravenously on days 1-5) followed by interferon-α-2a (2 × 106 U/m2 subcutaneously on days 22-26)
Number of subjects: 21
Study 12151972 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine and interferon-α-2a regimen
Number of subjects: 21
Study 9840032 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D MR DSA
Number of subjects: 22
Study 9840032 — intervention group
Group type: COMPARATOR
Intervention: X-ray Angiography (XRA)
Number of subjects: 22
Study 7988196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure (0.20 ppm)
Number of subjects: 10
Study 7988196 — intervention group
Group type: COMPARATOR
Intervention: Filtered Purified Air (FPA) exposure
Number of subjects: 10
Study 2726771 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric monoclonal antibody (mAb) 10 mg single infusion
Number of subjects: 10
Study 2726771 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric monoclonal antibody (mAb) 40 mg single infusion
Number of subjects: 10
Study 2726771 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric monoclonal antibody (mAb) 10 mg three infusions
Number of subjects: 10
Study 2726771 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric monoclonal antibody (mAb) 40 mg three infusions
Number of subjects: 10
Study 29512827 — intervention group
Group type: EXPERIMENTAL
Intervention: 170 mug LPP administered subcutaneously over 3 weeks
Number of subjects: 554
Study 25826476 — intervention group
Group type: EXPERIMENTAL
Intervention: Life story book
Number of subjects: 5
Study 25826476 — intervention group
Group type: EXPERIMENTAL
Intervention: Rummage box
Number of subjects: 5
Study 25826476 — intervention group
Group type: COMPARATOR
Intervention: No-intervention condition
Number of subjects: 5
Study 25424512 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Diet Quality + Weight Maintenance Intervention
Number of subjects: 0
Study 25424512 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Diet Quality + Weight Loss Intervention
Number of subjects: 0
Study 25424512 — intervention group
Group type: COMPARATOR
Intervention: Exercise Only (Control) Intervention
Number of subjects: 0
Study 24359543 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention for GPs including interactive workshops, audit and feedback reports, automated electronic prompts, and a recommendation for delayed antimicrobial treatment.
Number of subjects: 2038
Study 24359543 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia applications and information leaflets for patients.
Number of subjects: 2038
Study 20945468 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucommander
Number of subjects: 153
Study 18387160 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer (3.0 g/day)
Number of subjects: 62
Study 18387160 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestimide (3.0 g/day)
Number of subjects: 62
Study 18387160 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer with CaCO3 (3.0 g/day)
Number of subjects: 62
Study 18387160 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestimide with CaCO3 (3.0 g/day)
Number of subjects: 62
Study 16343856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin XR 1000 mg
Number of subjects: 12
Study 16343856 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500 mg
Number of subjects: 12
Study 14677216 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemiparesis patients
Number of subjects: 104
Study 14677216 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemiparesis patients
Number of subjects: 104
Study 14677216 — intervention group
Group type: COMPARATOR
Intervention: Functional ability assessment
Number of subjects: 104
Study 14677216 — intervention group
Group type: COMPARATOR
Intervention: Stance unsteadiness and asymmetry
Number of subjects: 104
Study 14677216 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 age-matched individuals)
Number of subjects: 104
Study 11273797 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanic acid
Number of subjects: 335
Study 11273797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study 9391723 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of heparin based on initial patient-specific dose per unit weight and adjustments during CPB based on reference heparin concentration.
Number of subjects: 40
Study 9391723 — intervention group
Group type: COMPARATOR
Intervention: Monitoring group using bolus administration of heparin calculated by the Hepcon instrument during CPB.
Number of subjects: 40
Study 9391723 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received similar doses of heparin and protamine, and had similar transfusion requirements.
Number of subjects: 40
Study 9391723 — intervention group
Group type: COMPARATOR
Intervention: Monitoring group prior to CPB.
Number of subjects: 40
Study 7933485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg)
Number of subjects: 0
Study 7933485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal buprenorphine (0.05 mg)
Number of subjects: 0
Study 7933485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal buprenorphine (0.075 mg)
Number of subjects: 0
Study 3328281 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1.0g qid for 4 days
Number of subjects: 24
Study 3328281 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate treatment
Number of subjects: 24
Study 3328281 — intervention group
Group type: COMPARATOR
Intervention: ASA treatment
Number of subjects: 24
Study 30698458 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray prior to SC heparin injection
Number of subjects: 64
Study 30698458 — intervention group
Group type: COMPARATOR
Intervention: Water spray (placebo) prior to SC heparin injection
Number of subjects: 64
Study 29600809 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) at 24 Gy to the 50% isodose targeting mesial structures
Number of subjects: 58
Study 29600809 — intervention group
Group type: COMPARATOR
Intervention: Anterior temporal lobectomy (ATL)
Number of subjects: 58
Study 29600809 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 58
Study 29600809 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SRS and ATL
Number of subjects: 58
Study 28611897 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based coaching intervention
Number of subjects: 69
Study 28611897 — intervention group
Group type: COMPARATOR
Intervention: Usual post-ED care
Number of subjects: 69
Study 25856270 — intervention group
Group type: EXPERIMENTAL
Intervention: POPET-AR group (mobile phone application for AR patients)
Number of subjects: 327
Study 25856270 — intervention group
Group type: EXPERIMENTAL
Intervention: POPET-Asthma group (mobile phone application for asthma patients)
Number of subjects: 327
Study 22718278 — intervention group
Group type: EXPERIMENTAL
Intervention: G135E mutation in HOXB13
Number of subjects: 96
Study 22718278 — intervention group
Group type: COMPARATOR
Intervention: Control group (1,536 subjects)
Number of subjects: 96
Study 22321976 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program, supervised for 6 sessions followed by home-based training.
Number of subjects: 50
Study 22321976 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise group (daily activities).
Number of subjects: 50
Study 18287414 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cytologic analysis
Number of subjects: 472
Study 18287414 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate subtyping
Number of subjects: 472
Study 16922471 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term donepezil therapy (3 months)
Number of subjects: 17
Study 16922471 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term donepezil therapy (1 year)
Number of subjects: 17
Study 16922471 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment levels
Number of subjects: 17
Study 16922471 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute rCBF
Number of subjects: 17
Study 12830444 — intervention group
Group type: EXPERIMENTAL
Intervention: Short daily HD
Number of subjects: 44
Study 12830444 — intervention group
Group type: EXPERIMENTAL
Intervention: Long nocturnal HD
Number of subjects: 44
Study 12830444 — intervention group
Group type: COMPARATOR
Intervention: Conventional thrice-weekly HD
Number of subjects: 44
Study 12830444 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily HD
Number of subjects: 44
Study 12830444 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal HD
Number of subjects: 44
Study 10831898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin alone
Number of subjects: 18
Study 10831898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 18
Study 10831898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin with Refresh Plus
Number of subjects: 18
Study 9342998 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management training
Number of subjects: 107
Study 9342998 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 107
Study 9342998 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 107
Study 9342998 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management
Number of subjects: 107
Study 30028930 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode Laser (DL)
Number of subjects: 74
Study 30028930 — intervention group
Group type: COMPARATOR
Intervention: Gingival Retraction Cords (RC)
Number of subjects: 74
Study 27664561 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 impulses of ESWT at 24 Kv (Group A)
Number of subjects: 33
Study 27664561 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 impulses of ESWT (Group B)
Number of subjects: 33
Study 27664561 — intervention group
Group type: EXPERIMENTAL
Intervention: 6000 impulses of ESWT (Group C)
Number of subjects: 33
Study 24860173 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (3-4 times per week for 8 weeks)
Number of subjects: 16
Study 24860173 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 16
Study 22327082 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV) training
Number of subjects: 10
Study 22327082 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 10
Study 19690268 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 40
Study 19690268 — intervention group
Group type: COMPARATOR
Intervention: 5% human albumin
Number of subjects: 40
Study 17021429 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-Technegas SPECT imaging
Number of subjects: 17
Study 17021429 — intervention group
Group type: EXPERIMENTAL
Intervention: 133Xe dynamic SPECT imaging
Number of subjects: 17
Study 17021429 — intervention group
Group type: COMPARATOR
Intervention: HRCT imaging
Number of subjects: 17
Study 15025654 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial load of 250 h and 45 kg
Number of subjects: 18
Study 15025654 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-axial load of 250 h and 45 kg
Number of subjects: 18
Study 15025654 — intervention group
Group type: COMPARATOR
Intervention: Control (unloaded tooth)
Number of subjects: 18
Study 11751742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 38
Study 9222672 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U/kg of r‐HuEPO divided in three doses (300 U/kg 12 days before surgery, 100 U/kg 4 and 8 days later)
Number of subjects: 20
Study 9222672 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U/kg of r‐HuEPO (300 U/kg)
Number of subjects: 20
Study 9222672 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U/kg of r‐HuEPO (100 U/kg)
Number of subjects: 20
Study 9222672 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery without delay)
Number of subjects: 20
Study 9222672 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (r‐HuEPO treatment)
Number of subjects: 20
Study 7678586 — intervention group
Group type: EXPERIMENTAL
Intervention: HibCP-TT followed by HibCP-DT
Number of subjects: 82
Study 7678586 — intervention group
Group type: EXPERIMENTAL
Intervention: HibCP-DT followed by HibCP-TT
Number of subjects: 82
Study 7678586 — intervention group
Group type: COMPARATOR
Intervention: Preimmunization with carrier protein (TT or DT)
Number of subjects: 82
Study 3616754 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotic analgesic (meperidine hydrochloride) plus antispasmodics (diazepam and baclofen)
Number of subjects: 50
Study 3616754 — intervention group
Group type: COMPARATOR
Intervention: Narcotic analgesic (meperidine hydrochloride) alone
Number of subjects: 50
Study 31948462 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-driven surgical safety checklist
Number of subjects: 52
Study 31948462 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group interviews
Number of subjects: 52
Study 29708654 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel pocket irrigator/evacuator device (IED)
Number of subjects: 25
Study 29708654 — intervention group
Group type: COMPARATOR
Intervention: Conventional subgingival debridement (CPT)
Number of subjects: 25
Study 29708654 — intervention group
Group type: EXPERIMENTAL
Intervention: IED
Number of subjects: 25
Study 29708654 — intervention group
Group type: COMPARATOR
Intervention: CPT
Number of subjects: 25
Study 27515838 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-home training on box trainers
Number of subjects: 18
Study 23963049 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-only strategies
Number of subjects: 192
Study 23963049 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal + visual strategies
Number of subjects: 192
Study 23963049 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 192
Study 23635616 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal residue diet plus mechanical bowel preparation with oral sodium picosulphate
Number of subjects: 308
Study 23635616 — intervention group
Group type: COMPARATOR
Intervention: Fasting only
Number of subjects: 308
Study 23635616 — intervention group
Group type: COMPARATOR
Intervention: Minimal residue diet for 2 days
Number of subjects: 308
Study 23635616 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal residue diet plus mechanical bowel preparation
Number of subjects: 308
Study 19558378 — intervention group
Group type: EXPERIMENTAL
Intervention: History of previous acute ankle injuries
Number of subjects: 508
Study 19558378 — intervention group
Group type: EXPERIMENTAL
Intervention: FAOS sub-score 'Pain'
Number of subjects: 508
Study 19558378 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional tests and clinical examination
Number of subjects: 508
Study 17884341 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri E Tocotrienol 160 mg daily for 6 months
Number of subjects: 64
Study 16965592 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 UI per kg rHuEPO
Number of subjects: 32
Study 16965592 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 UI per kg rHuEPO
Number of subjects: 32
Study 16965592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12768071 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 28
Study 12768071 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 28
Study 12768071 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 28
Study 11203592 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA gel
Number of subjects: 91
Study 11203592 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EDTA gel)
Number of subjects: 91
Study 11203592 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral patients
Number of subjects: 91
Study 11203592 — intervention group
Group type: COMPARATOR
Intervention: Maintenance care patients
Number of subjects: 91
Study 9337677 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon (IFN)
Number of subjects: 280
Study 9337677 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 280
Study 8409113 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (50, 300, 600 mg doses; half doses for subjects weighing less than 40 kg)
Number of subjects: 21
Study 8409113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8409113 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 21
Study 3531314 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g daily for 5 weeks
Number of subjects: 60
Study 3531314 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 weeks
Number of subjects: 60
Study 29737256 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 9340
Study 29737256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9340
Study 28642811 — intervention group
Group type: EXPERIMENTAL
Intervention: Actinidia chinensis Planch. juice
Number of subjects: 0
Study 28642811 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without taking the juice)
Number of subjects: 0
Study 25884778 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclegis® (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg)
Number of subjects: 256
Study 25884778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 23727316 — intervention group
Group type: EXPERIMENTAL
Intervention: pICA-R
Number of subjects: 300
Study 21680022 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 137
Study 21680022 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% (0.25% for those aged <3 years)
Number of subjects: 137
Study 21680022 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% (PCG subgroup)
Number of subjects: 137
Study 21680022 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% (PCG subgroup)
Number of subjects: 137
Study 21680022 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% (non-PCG subgroup)
Number of subjects: 137
Study 21680022 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% (non-PCG subgroup)
Number of subjects: 137
Study 18626766 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisis Residential Program (CRP)
Number of subjects: 393
Study 18626766 — intervention group
Group type: COMPARATOR
Intervention: Locked Inpatient Psychiatric Facility (LIPF)
Number of subjects: 393
Study 16863773 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump surgery
Number of subjects: 212
Study 16863773 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 212